Effects of recombinant human granulocyte colony-stimulating factor on the growth potential of two murine myeloid leukemias. 1996

K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
Pharmaceutical Research Laboratory, Kirin Brewery Co. Ltd, Gunma, Japan.

We investigated the in vitro and in vivo effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on the proliferation of two murine leukemic cell lines. The rhG-CSF stimulated leukemic colony formation of the promyelocytic leukemic cell line L-8801 in methylcellulose culture and increased the number of L-8801 cells in liquid culture. However, rhG-CSF treatment prolonged the median survival period of mice implanted with L-8801 cells and the emergence of the leukemic blast cells in peripheral blood. Meanwhile, rhG-CSF had no influence on that of the megakaryoblastic leukemic cells L-8057 and failed to prolong the median survival period of L-8057 leukemic mice. Receptor binding analysis revealed that L-8801 cells expressed a G-CSF receptor (Kd=125 pM, 479 binding sites/cell) and L-8057 cells had no G-CSF receptors. Then, we examined the growth potential of these cells. The median survival period was longer for mice implanted with L-8801 cells cultured with rhG-CSF for 72 h in vitro than for cells grown without rhG-CSF. Furthermore, the median survival period of mice implanted with spleen cells from L-8801 leukemic mice treated with rhG-CSF was prolonged compared with those from leukemic mice without rhG-CSF. In contrast, there was no effect of rhG-CSF on the growth potential of the spleen from L-8057 leukemic mice. The results of our present study demonstrate that rhG-CSF reduced the growth of L-8801 leukemic cells in vitro and in vivo mediated through G-CSF receptors, thereby suppressing the development of leukemia.

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D016179 Granulocyte Colony-Stimulating Factor A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. Colony-Stimulating Factor, Granulocyte,G-CSF,Myeloid Growth Factor,Colony Stimulating Factor, Granulocyte,Factor, Granulocyte Colony-Stimulating,Factor, Myeloid Growth,Granulocyte Colony Stimulating Factor,Growth Factor, Myeloid
D016188 Receptors, Granulocyte Colony-Stimulating Factor Receptors that bind and internalize GRANULOCYTE COLONY-STIMULATING FACTOR. Their MW is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells. G-CSF Receptors,G-CSF Receptor,Granulocyte Colony-Stimulating Factor Receptors,Receptor, Granulocyte Colony-Stimulating Factor,Receptors, G-CSF,G CSF Receptor,G CSF Receptors,Granulocyte Colony Stimulating Factor Receptors,Receptor, G-CSF,Receptor, Granulocyte Colony Stimulating Factor,Receptors, G CSF,Receptors, Granulocyte Colony Stimulating Factor

Related Publications

K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
April 1986, Science (New York, N.Y.),
K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
October 1987, Experimental hematology,
K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
October 1993, Blood,
K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
January 1988, Journal of immunology (Baltimore, Md. : 1950),
K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
July 1988, Blood,
K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
April 1989, Seminars in hematology,
K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
March 1990, Leukemia,
K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
March 1987, The Journal of clinical investigation,
K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
August 1988, Behring Institute Mitteilungen,
K Kabaya, and M Obuchi, and T Kuwaki, and K Shibuya, and M Watanabe, and K Nemoto, and K Yoshida, and M Kusaka, and T Inoue, and M Seki
January 1998, Acta physiologica, pharmacologica et therapeutica latinoamericana : organo de la Asociacion Latinoamericana de Ciencias Fisiologicas y [de] la Asociacion Latinoamericana de Farmacologia,
Copied contents to your clipboard!